| Ytd | 12.80% | |
| 1y | 161.88% |
| Open | 23.51 | Prev Close | 23.46 | Low | 22.86 | High | 24.50 | Mkt Cap | 347.87M |
| Vol | 84.79K | Avg Vol | 141.89K | EPS | -1.61 | P/E | N/A | Forward P/E | -14.83 |
| Beta | 3.32 | Short Ratio | 21.41 | Inst. Own | 8.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 24.15 | 200-d Avg | 19.64 | 1yr Est | 38.00 |
GLSI News
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the
from the ASCO Annual Meeting 2026.The abstract is shown below and the poster being presented today c
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinica
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shares are trading higher after the company announced the
BABA: 5% | Alibaba shares are trading higher on Bloomberg report of company moving toward IPO of its
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy
Greenwich LifeSciences shares are trading higher Monday after the company announced it extended its
Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streaml
Greenwich LifeSciences stock rose after Phase 3 data showed GLSI-100 cut breast cancer recurrence ra
A preliminary analysis of recurrence rates by two methods to estimate the reduction in recurrence ra
In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are currently
Flamingo-01 Progress to DateThe Company has achieved a major milestone by screening over 1,000 patie
The Company's application to European regulators has been formally approved, adding Belgium as a
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutic
On Monday, 369 companies set new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
Gainers Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported c
During Wednesday's morning trading, 400 companies set new 52-week lows.
Gainers
Gainers
Gainers
Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its C
Gainers Greenwich Lifesciences Inc (NASDAQ: GLSI) shares jumped 998.1% to close at $57.10 on Wedn